TOTAL Padova
group
Udine
group
Cancer site/type
(ICD-10)
Obs.
Tot. (PD/UD)
IR
*100.000
SIR 95% CI  SIR (95% CI)  SIR (95% CI)
             
Head and neck (C00-14 and 30, 32) 7(4/3) 231.4 4.6 1.3-11.9 4.4 (0.5-16.1) 4.8 (0.6-17.5)
Esophagus (C15) 5 (3/2) 171.8 18.7 3.9-54.7 12.1 (0.3-67.6) 25.7 (3.1-92.9)
Stomach (C16) 3(2/1) 171.3 4.3 0.9-12.6 5.6 (0.7-20.4) 2.9 (0.1-16.4)
Colon (C18) 2(2/0) 114.9 2.5 0.3-9.2 5.2 (0.6-18.8) NC
Lung (C34) 4 (2/2) 114.2 0.9 0.1-3.2 0.9 (0.0-4.8) 0.9 (0.0-5.2)
Melanoma of skin (C43) 2 (1/1) 114.4 10.1 1.2-36.3 9.5 (0.2-53.2) 10.6 (0.3-59.2)
Kaposi’s sarcoma (C46) 6 (6/0) 291.5 211.6 68.7-493.8 370.2 (120.2-863.9) NC
Breast, female (C50) 1(0/1) 193.3 1.2 0.0-6.7 NC 2.1 (0.1-12.0)
Cervix uteri (C53) 2 (2/0) 192.8 12.8 0.3-71.4 28.1 (0.7-156.5) NC
Non Hodgkin’s Lymphoma (C82-85,C96) 8 (3/5) 286.7 13.7 4.5-32.0 10.7 (1.3-38.7) 16.9 (3.5-49.3)
             
All cancers but skin 40 (25/15) 1822.1 3.0 2.0-4.3 4.0 (2.4-6.2) 2.1 (1.1-3.8)
NC: the SIR was not computed because no cancer cases were observed
Table 3: incidences rates (IR) (*100.000) and standardized incidence ratios (SIR) with 95 confidence intervals (CI) according to cancer site/type and transplant.